531 related articles for article (PubMed ID: 10836293)
41. Long term follow-up of a large series of stage-II/III atypical proliferative serous ovarian tumors.
Maria S; Faron M; Maulard A; Pautier P; Leary A; Chargari C; Genestie C; Gouy S; Morice P
Gynecol Oncol; 2020 Sep; 158(3):659-665. PubMed ID: 32571680
[TBL] [Abstract][Full Text] [Related]
42. The pathology of and controversial aspects of ovarian borderline tumours.
McCluggage WG
Curr Opin Oncol; 2010 Sep; 22(5):462-72. PubMed ID: 20531187
[TBL] [Abstract][Full Text] [Related]
43. KRAS mutation in primary ovarian serous borderline tumors correlates with tumor recurrence.
McHenry A; Rottmann DA; Buza N; Hui P
Virchows Arch; 2023 Jul; 483(1):71-79. PubMed ID: 37219599
[TBL] [Abstract][Full Text] [Related]
44. Ovarian tumors of borderline malignancy (tumors of low malignant potential): a critical appraisal.
Prat J
Adv Anat Pathol; 1999 Sep; 6(5):247-74. PubMed ID: 10472378
[TBL] [Abstract][Full Text] [Related]
45. The presence and location of epithelial implants and implants with epithelial proliferation may predict a higher risk of recurrence in serous borderline ovarian tumors: a clinicopathologic study of 188 cases.
Quddus MR; Sung CJ; Zhang C; Moore RG; Ou JJ; Steinhoff MM; Lawrence WD
Hum Pathol; 2012 May; 43(5):747-52. PubMed ID: 22047646
[TBL] [Abstract][Full Text] [Related]
46. Recent developments on the significance and pathogenesis of lymph node involvement in ovarian serous tumors of low malignant potential (borderline tumors).
Fadare O
Int J Gynecol Cancer; 2009 Jan; 19(1):103-8. PubMed ID: 19258950
[TBL] [Abstract][Full Text] [Related]
47. Diverse tumorigenic pathways in ovarian serous carcinoma.
Singer G; Kurman RJ; Chang HW; Cho SK; Shih IeM
Am J Pathol; 2002 Apr; 160(4):1223-8. PubMed ID: 11943707
[TBL] [Abstract][Full Text] [Related]
48. Serous carcinoma of the ovary and peritoneum with metastases to the breast and axillary lymph nodes: a potential pitfall.
Recine MA; Deavers MT; Middleton LP; Silva EG; Malpica A
Am J Surg Pathol; 2004 Dec; 28(12):1646-51. PubMed ID: 15577686
[TBL] [Abstract][Full Text] [Related]
49. Low-grade Serous Carcinoma of the Ovary: Clinicopathologic Analysis of 52 Invasive Cases and Identification of a Possible Noninvasive Intermediate Lesion.
Ahn G; Folkins AK; McKenney JK; Longacre TA
Am J Surg Pathol; 2016 Sep; 40(9):1165-76. PubMed ID: 27487741
[TBL] [Abstract][Full Text] [Related]
50. KRAS mutation of extraovarian implants of serous borderline tumor: prognostic indicator for adverse clinical outcome.
Zuo T; Wong S; Buza N; Hui P
Mod Pathol; 2018 Feb; 31(2):350-357. PubMed ID: 29027536
[TBL] [Abstract][Full Text] [Related]
51. Evaluation of diagnostic criteria and behavior of ovarian intestinal-type mucinous tumors: atypical proliferative (borderline) tumors and intraepithelial, microinvasive, invasive, and metastatic carcinomas.
Riopel MA; Ronnett BM; Kurman RJ
Am J Surg Pathol; 1999 Jun; 23(6):617-35. PubMed ID: 10366144
[TBL] [Abstract][Full Text] [Related]
52. [Diagnostic difficulties in serous "borderline" tumors of the ovary].
Vereczkey I; Tóth E; Orosz Z
Magy Onkol; 2009 Mar; 53(1):23-31. PubMed ID: 19318323
[TBL] [Abstract][Full Text] [Related]
53. Lymph node involvement in ovarian serous tumors of low malignant potential (borderline tumors): pathology, prognosis, and proposed classification.
McKenney JK; Balzer BL; Longacre TA
Am J Surg Pathol; 2006 May; 30(5):614-24. PubMed ID: 16699316
[TBL] [Abstract][Full Text] [Related]
54. Borderline epithelial tumors of the ovary.
Hart WR
Mod Pathol; 2005 Feb; 18 Suppl 2():S33-50. PubMed ID: 15761465
[TBL] [Abstract][Full Text] [Related]
55. Quantitative analysis of follicle-stimulating hormone receptor in ovarian epithelial tumors: a novel approach to explain the field effect of ovarian cancer development in secondary mullerian systems.
Wang J; Lin L; Parkash V; Schwartz PE; Lauchlan SC; Zheng W
Int J Cancer; 2003 Jan; 103(3):328-34. PubMed ID: 12471615
[TBL] [Abstract][Full Text] [Related]
56. Ovarian serous borderline tumors with invasive peritoneal implants.
Gershenson DM; Silva EG; Levy L; Burke TW; Wolf JK; Tornos C
Cancer; 1998 Mar; 82(6):1096-103. PubMed ID: 9506355
[TBL] [Abstract][Full Text] [Related]
57. Late recurrence of pStage 1 low-grade serous ovarian tumor presenting as a symptomatic bone metastasis: a case report.
Kubo C; Nagata S; Fukuda T; Kano R; Tanaka T; Nakanishi K; Ohsawa M; Nakatsuka SI
Diagn Pathol; 2018 Jun; 13(1):43. PubMed ID: 29960592
[TBL] [Abstract][Full Text] [Related]
58. Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria.
Hauptmann S; Friedrich K; Redline R; Avril S
Virchows Arch; 2017 Feb; 470(2):125-142. PubMed ID: 28025670
[TBL] [Abstract][Full Text] [Related]
59. Serous tumors of low malignant potential of the ovary. 1. Diagnostic pathology.
Dietel M; Hauptmann S
Virchows Arch; 2000 May; 436(5):403-12. PubMed ID: 10881733
[TBL] [Abstract][Full Text] [Related]
60. Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors.
Gershenson DM; Deavers M; Diaz S; Tortolero-Luna G; Miller BE; Bast RC; Mills GB; Silva EG
Clin Cancer Res; 1999 Dec; 5(12):4053-8. PubMed ID: 10632339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
